Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.60 |
| ▸ | CA2 | P00918 | 8/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.58 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | UQCRB | P14927 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6690731 | 0.87 | CA1 (0.54) | CA1CA2TRPV1 | |
| SCHEMBL6692382 | 0.81 | PTGS2 (0.51) | GHSRPTGS2 | |
| SCHEMBL6693546 | 0.80 | FFAR1 (0.49) | GHSRPTGS2MAPT | |
| SCHEMBL6696110 | 0.80 | RXFP1 (0.46) | GHSRPTGS2 | |
| SCHEMBL7207001 | 0.78 | CA1 (0.47) | CA1CA2IKBKBTRPV1GAA | |
| SCHEMBL6693419 | 0.77 | PTGS2 (0.47) | PTGS2 | |
| SCHEMBL1241386 | 0.77 | CA1 (0.48) | CA1CA2TRPV1SMN1; SMN2 | |
| SCHEMBL6692374 | 0.76 | CA1 (0.45) | CA1CA2TRPV1 | |
| SCHEMBL7995375 | 0.75 | CA1 (0.59) | CA1CA2EPHX2NR1H4 | |
| SCHEMBL1107981 | 0.74 | ALDH1A1 (0.64) | CA1CA2EPHX2NR1H4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | 4SC AG (DE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003076388-A2 | BIS-ANILINE DERIVATIVES USEFUL AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | PAH, PNMT, OPRM1 | CA1 2457/4885CA2 1332/4885EPHX2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.